Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.61 |
| ▸ | MAOB | P27338 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | MIF | P14174 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL28679828 | 0.98 | TAAR1 (0.59) | TAAR1MAOBMEN1KMT2AMIF | |
| SCHEMBL3740709 | 0.98 | TAAR1 (0.59) | TAAR1MAOBMEN1KMT2AMIF | |
| SCHEMBL5511977 | 0.94 | MAOB (0.63) | TAAR1MAOBMEN1KMT2AMIF | |
| Fluorobenzene SCHEMBL27753953 | 0.87 | TDP1 (0.52) | TAAR1MAOBMEN1KMT2AMIF | |
| SCHEMBL79100 | 0.86 | TAAR1 (0.57) | TAAR1MAOBMIFIDO1PTPN1 | |
| Toluene SCHEMBL28782454 | 0.85 | TDP1 (0.50) | TAAR1MAOBMEN1KMT2AMIF | |
| SCHEMBL934227 | 0.85 | TAAR1 (0.73) | TAAR1MAOBMIFIDO1HDAC1 | |
| SCHEMBL5781780 | 0.85 | TAAR1 (0.55) | TAAR1MAOBMIFIDO1PTPN1 | |
| SCHEMBL3484834 | 0.83 | TAAR1 (0.53) | TAAR1MAOBMIFIDO1PTPN1 | |
| SCHEMBL11395535 | 0.83 | TAAR1 (0.53) | TAAR1MAOBMIFIDO1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3860636-B1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | DISC MEDICINE INC (US) | 2026-01-28 | — | — | EP | disclosed |
| US-12428415-B2 | Matriptase 2 inhibitors and uses thereof | DISC MEDICINE, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| WO-2025129168-A1 | TRIAZOLONE INHIBITORS OF NICOTINAMIDE N-METHYLTRANSFERASE AND THEIR THERAPEUTIC USES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2025-06-12 | — | — | US | disclosed |
| CN-113072546-B | Five-membered heteroaromatic derivative and preparation method and application thereof | 广东东阳光药业股份有限公司 | 2025-05-30 | — | — | CN | disclosed |
| WO-2025104092-A1 | MODULATORS OF SEPTIN 6 FOR USE IN THE PREVENTION AND/OR TREATMENT OF NEURODEGENERATIVE DISORDERS | REMYND N.V. (BE) | 2025-05-22 | — | — | WO | disclosed |
| WO-2025104081-A1 | TRIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS | REMYND N.V. (BE) | 2025-05-22 | — | — | WO | disclosed |
| CN-119894866-A | YAP/TAZ-TEAD oncoprotein inhibitors | 布里奇恩生物科学公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-119528906-A | Azaspiro compound, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2025-02-28 | — | — | CN | disclosed |
| WO-2024229262-A1 | NARROW-SPECTRUM ANTIBIOTIC COMPOUNDS AND USES THEREOF | MCMASTER UNIVERSITY (CA) | 2024-11-07 | — | — | WO | disclosed |
| US-5670085-A | Liquid crystalline compound and liquid crystal | CHISSO CORPORATION (JP) | 1997-09-23 | — | — | US | disclosed |
| WO-1997019073-A1 | PIPERIDINE AND TETRAHYDROPYRIDINE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1997-05-29 | — | — | WO | disclosed |
| EP-0492474-B1 | 1,3-Dioxolane derivatives as cholesterol-lowering agents | SYNTEX INC (US) | 1997-03-05 | — | — | EP | disclosed |
| US-5534187-A | CONTAINING CYCLOHEXANE RING | CHISSO CORPORATION (JP) | 1996-07-09 | — | — | US | disclosed |
| EP-0718264-A1 | A liquid crystalline compound containing fluorine atom substituted alkyl group(s) and a liquid crystal composition | Chisso Corporation (JP) | 1996-06-26 | — | — | EP | disclosed |
| EP-0675187-A2 | Liquid crystalline compounds and liquid crystal composition | Chisso Corporation (JP) | 1995-10-04 | — | — | EP | disclosed |
| US-5158949-A | 1,3-DIOXOLANE DERIVATIVES AS CHOLESTEROL-LOWERING AGENTS | SYNTEX (U.S.A.) INC. (US) | 1992-10-27 | — | — | US | disclosed |
| EP-0492474-A1 | 1,3-Dioxolane derivatives as cholesterol-lowering agents | SYNTEX (U.S.A.) INC. (US) | 1992-07-01 | — | — | EP | disclosed |
| US-4150135-A | ANALGESICS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1979-04-17 | — | — | US | disclosed |
| US-3936462-A | CNS DEPRESSANT, ANALGESIC | STERLING DRUG INC. (US) | 1976-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428415-B2 | Matriptase 2 inhibitors and uses thereof | MMP7, MATR3, SPINT2 | TAAR1 4350/4885MAOB 332/4885MEN1 772/4885 |
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | KMT5A, KMT5B, KMT5C | TAAR1 3002/4885MAOB 648/4885MEN1 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.